Verona Pharma PLC To Discuss The Phase 3 ENHANCE Data Presented At ATS 2023 Transcript
Good day, and welcome to the Verona Pharma ATS 2023 data call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to David Zaccardelli, Chief Executive Officer. Please go ahead.
Good afternoon, everyone. Thank you for joining the call. With me today are Dr. Tara Rheault, our Head of Research and Development; Dr. Kathy Rickard, our Chief Medical Officer; Chris Martin, Head of Commercial; and Mark Hahn, our Chief Financial Officer. Before we begin, let me remind you that we may be making forward-looking statements, and as such, refer you to our risk section in our recent SEC filings.
It has been a very exciting and productive past few days at the ATS meeting in Washington, D.C. Ensifentrine has been on full display with a comprehensive review of the Phase III ENHANCE trial results. This has included a symposium presentation and 12 abstracts, including subset analyses and pooled analyses from ENHANCE-1 and ENHANCE-2
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
